Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Ligands for Non-Canonical DNA Structures: Do They Have a Future in Medicinal Chemistry?

International journal of molecular sciences·2022
Same author

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic.

Bioorganic & medicinal chemistry letters·2022
Same author

Targeting Canine <i>KIT</i> Promoter by Candidate DNA G-Quadruplex Ligands.

The Journal of pharmacology and experimental therapeutics·2018
Same author

Highly Improved Electrospray Ionization-Mass Spectrometry Detection of G-Quadruplex-Folded Oligonucleotides and Their Complexes with Small Molecules.

Analytical chemistry·2017
Same author

Discovery of <sup>wt</sup> RET and <sup>V804M</sup> RET Inhibitors: From Hit to Lead.

ChemMedChem·2017
Same author

Virtual Cross-Linking of the Active Nemorubicin Metabolite PNU-159682 to Double-Stranded DNA.

Chemical research in toxicology·2017

Related Experiment Video

Updated: Jan 13, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K

Anticancer agents: towards the future.

Manlio Palumbo1

  • 1Department of Pharmaceutical Sciences, Via Marzolo, 5, 35131 Padova, Italy. manlio.palumbo@unipd.it

Current Medicinal Chemistry. Anti-Cancer Agents
|September 24, 2004
PubMed
Summary

Developing cancer cell-specific drugs is crucial for chemotherapy. This paper reviews advances in selective drug recognition targeting tyrosine kinases, DNA-topoisomerases, and telomerase for improved cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chemotherapy faces challenges with non-specific drug action, leading to side effects.
  • The development of targeted cancer therapies is a significant unmet need.
  • Selective drug recognition offers a promising strategy to enhance therapeutic efficacy and reduce toxicity.

Purpose of the Study:

  • To review recent advancements in selective drug recognition for cancer chemotherapy.
  • To discuss the potential of targeting key molecules like tyrosine kinases, DNA-topoisomerases, and telomerase.
  • To provide perspectives on future directions in the development of cancer cell-specific drugs.

Main Methods:

  • Literature review of recent research in targeted cancer therapy.
  • Analysis of drug recognition mechanisms for specific molecular targets.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K
  • Discussion of emerging strategies in medicinal chemistry and drug design.

    • Main Results:

    • Significant progress has been made in identifying and targeting key cancer-related molecules.
    • Selective inhibitors for tyrosine kinases, DNA-topoisomerases, and telomerase show therapeutic promise.
    • The field is advancing towards more precise and effective cancer treatments.

    Conclusions:

    • Selective drug recognition is a vital strategy for developing next-generation cancer chemotherapies.
    • Targeting tyrosine kinases, DNA-topoisomerases, and telomerase offers distinct avenues for drug development.
    • Continued research in this area is essential for improving patient outcomes in cancer treatment.